Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
Industry: PharmaceuticalsMajor

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Current Quote*
Last: $16.720
Change: -0.530
Book: $3.076
Volume: 187,579

As Of: 03/22 13:33 ET
*Quotes delayed by 20min.

Graphs for KNSA

3 Month Graph

6 Month Graph

1 Year Graph